Skip to main content

Breadcrumb

  1. Home

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Phase 2/3 Adaptive Study of VX-147 in Adults and Adolescents With APOL1- Mediated Proteinuric Kidney Disease

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Phase 2/3 Adaptive Study of VX-147 in Adults and Adolescents With APOL1- Mediated Proteinuric Kidney Disease

Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 38
  • Page 39
  • Page 40
  • Page 41
  • Page 42
  • Page 43
  • Page 44
  • Page 45
  • Page 46
  • …
  • Next page Next
  • Last page Last
Subscribe to